智通财经APP讯，康臣药业(01681)公布，于2025年11月6日，该公司斥资150.09万港元回购10万股股 份，每股回购价格为15-15.04港元。 ...

公司名稱： 康臣葯業集團有限公司 呈交日期： 2025年11月6日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售 ...

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company repurchased 200,000 shares at a total cost of HKD 2.98 million [1] - The buyback price ranged from HKD 14.81 to HKD 15 per share [1]

Core Viewpoint - 康臣药业 announced a share buyback plan, intending to repurchase 200,000 shares at a cost of approximately HKD 2.9823 million on November 5, 2025 [1] Company Summary - 康臣药业 plans to execute a share buyback, which may indicate confidence in its financial position and a strategy to enhance shareholder value [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康臣葯業集團有限公司 呈交日期： 2025年11月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01681 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關 ...

Summary of Key Points Core Viewpoint - On November 4, 38 Hong Kong-listed companies conducted share buybacks, totaling 62.68 million shares and an aggregate amount of HKD 294 million [1][2]. Group 1: Buyback Details - China Feihe repurchased 18 million shares for HKD 76.11 million, with a highest price of HKD 4.260 and a lowest price of HKD 4.210, bringing its total buyback amount for the year to HKD 233 million [1][2]. - COSCO Shipping Holdings repurchased 4.5 million shares for HKD 61.70 million, with a highest price of HKD 13.960 and a lowest price of HKD 13.600, accumulating a total buyback amount of HKD 45.30 billion for the year [1][2]. - Pacific Shipping repurchased 10 million shares for HKD 26.09 million, with a highest price of HKD 2.640 and a lowest price of HKD 2.580, totaling HKD 22.91 million in buybacks for the year [1][2]. Group 2: Notable Companies - The largest buyback amount on November 4 was by China Feihe at HKD 76.11 million, followed by COSCO Shipping Holdings at HKD 61.70 million [1][2]. - In terms of share quantity, China Feihe led with 18 million shares repurchased, followed by Pacific Shipping with 10 million shares and Sinopec with 5.15 million shares [1][2]. - Noteworthy is that companies like Fenbi and Taimei Medical Technology conducted their first buybacks of the year on this date [2].

Summary of Key Points Core Viewpoint - 康臣药业 has been actively repurchasing its shares, indicating a strategy to support its stock price amidst recent declines [2]. Share Buyback Details - On November 4, 康臣药业 repurchased 495,000 shares at a price range of HKD 14.460 to HKD 14.910, totaling HKD 7.3134 million [2]. - The stock closed at HKD 14.890 on the same day, reflecting a decrease of 1.26% with a total trading volume of HKD 35.1134 million [2]. - Since October 14, the company has conducted buybacks for 15 consecutive days, acquiring a total of 3.696 million shares for a cumulative amount of HKD 56.0194 million, during which the stock price has dropped by 6.94% [2]. - Year-to-date, 康臣药业 has executed 33 buybacks, totaling 8.891 million shares and an aggregate amount of HKD 115 million [2]. Buyback Transaction Summary - A detailed table of buyback transactions shows the number of shares repurchased, highest and lowest prices, and total amounts for each transaction from July to November 2025 [3].

Group 1 - The company, 康臣药业 (01681), announced a share buyback plan on November 4, 2025, involving an expenditure of HKD 7.3134 million to repurchase 495,000 shares [1] - The buyback price range is set between HKD 14.46 and HKD 14.91 per share [1]

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Group 1: Buyback Details - The company repurchased 495,000 shares at a total cost of HKD 7.3134 million [1] - The buyback price ranged from HKD 14.46 to HKD 14.91 per share [1]

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Summary by Category Company Actions - 康臣药业 plans to repurchase 495,000 shares at a total cost of HKD 7.3134 million [1] - The buyback price ranges from HKD 14.46 to HKD 14.91 per share [1]